New study tests which drug combo best protects kidneys in hypertensive patients
NCT ID NCT07223502
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial compares two treatments for people with high blood pressure and chronic kidney disease: finerenone versus a fixed-dose combination of torsemide and spironolactone. The study will enroll 30 adults to see which approach better lowers blood pressure, reduces protein in urine, and keeps potassium levels safe. The goal is to find a more effective way to manage both conditions together.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
finerenone and a fixed-dose combination of extended-release torsemide and spironolactone
What this could lead to
If this trial succeeds, it could point toward a more effective treatment option for managing high blood pressure and kidney disease with fewer side effects.
What could go wrong
This is a small early-phase trial with only 30 participants, so results may not apply to everyone. The study compares two existing drugs, so no breakthrough is expected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sarfez Pharmaceuticals, Inc.
RECRUITINGVienna, Virginia, 22182, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact